Seres Therapeutics, Inc. · NASDAQ:MCRB
Seres Therapeutics — Q4 2015 Earnings Presentation
12 slides from Seres Therapeutics's earnings presentation, Feb 25, 2016
Slide 1: Q4 2015 Earnings Announcement and Business Update
Leading the Microbiome Revolution Q4 2015 Earnings Announcement and Business Update February 25, 2016
Slide 2: Agenda and Participants
Agenda and Participants Carlo Tanzi PhD, Head of Investor Relations Introduction and Corporate Communications Roger Pomerantz MD, President, Chief Progress Review Executive Officer and Chairman Financial Results and Eric Shaff, Chief Financial Officer Guidance Roger Pomerantz MD, President, Chief Cl
Slide 3: Forward Looking Statements
Forward Looking Statements Seres Therapeutics cautions that statements in this presentation (including oral commentary that accompanies this presentation) contains forward looking statements, including statements about our business strategy, prospective products, product approvals, development miles
Slide 4: Milestones Achieved
Milestones Achieved • Successful SER-109 Phase 1b/2 study readout • SER-109 Breakthrough & Orphan designations • SER-109 Phase 2 initiation • Successful Initial Public Offering • Patent portfolio expanded • SER-287 ulcerative colitis Phase 1b study initiated • Nestle Health Science strategic collabo
Slide 5: Collaboration with Nestlé Health Science
Collaboration with Nestlé Health Science • Nestlé Health Science global reach and GI market focus to support worldwide development and commercialization • Licensing rights for Seres C. difficile and inflammatory bowel disease assets for markets outside the US / Canada • $120M upfront, additional $30
Slide 6: SER-287 Phase 1b Study in Ulcerative Colitis
SER-287 Phase 1b Study in Ulcerative Colitis • Diverse spore ecology derived from healthy donors SER-287 • Repeat administration provides chronic ecological pressure to Overview correct microbiome dysbiosis • Repeat-dose placebo-controlled FMT studies show significant Therapeutic clinical response1
Slide 7: SER-287 Phase 1b Will Provide Insight into Efficacy and Mechanism in Ulcerative Colitis
SER-287 Phase 1b Will Provide Insight into Efficacy and Mechanism in Ulcerative Colitis Arm A (n=15): Placebo Primary Objective pre-treatment / Once • Change in composition of intestinal weekly dosing for 8 weeks microbiome at 8 weeks • Safety and tolerability Arm B (n=10): Placebo pre-treatment / O
Slide 8: Strong Financial Position
Strong Financial Position • Seres Cash balance of $205.1M at Dec. 31, 2015 • Nestlé Health Science transaction provided $120M upfront. Expect additional $30M during 2016 upon completing SER-109 and SER-262 milestones. • Expect existing cash to fund operating expenses and capital requirements well in
Slide 9: SER-262: Designed Ecobiotic® Lead in Development for Primary C. difficile
SER-262: Designed Ecobiotic® Lead in Development for Primary C. difficile Efficacy in C. difficile Murine Prophylaxis Model Efficacy in C. difficile Hamster Relapse Model Weight Loss & Mortality Survival Curve No Treatment Ctrl SER-262 SER-262 Vancomycin Ctrl 6 deaths 0 deaths No Treatment Ctrl SER-
Slide 10: Robust Microbiome Therapeutics Pipeline
Robust Microbiome Therapeutics Pipeline Discovery Preclinical Phase I Phase II Phase III SER-109 Recurrent C. difficile SER-262 Designed Ecobiotic® for Primary C. difficile SER-287 IBD (Ulcerative Colitis) SER-155 Drug resistant bacteria HSCT – GvHD + Bacteremia SER-301 Designed Ecobiotic® IBD Metab
Slide 11: Expected Value-Driving Milestones
Expected Value-Driving Milestones 1H 2016 2H 2016 2017+ Recurrent CDI: SER-109 Phase 2 Read-out Phase 3 initiation Primary CDI: SER-262 Phase 1 initiation Advancing new pipeline programs (infectious, inflammatory and metabolic diseases) 11
Slide 12: Question & Answer
Leading the Microbiome Revolution Question & Answer